Unity Biotech (NASDAQ: UBX) is developing drug candidates to extend the number of years humans can live unburdened by disease, but investors might appreciate it if the small-cap pharma focused just a little bit more on extending the price of shares.
The stock is trading at all-time lows (though "all-time" is just since its IPO in mid-2018). The company's lead drug candidate delivered mixed results in a phase 1 clinical trial in June, although the company characterized the results as "promising" and is moving ahead with a phase 2 study.
Wall Street clearly isn't enamored, but Unity Biotech has a deep pipeline of preclinical assets and exited June with $128 million in cash. Besides, investors might be intrigued by a company attempting to enable healthy aging. Should investors consider the stock a buy at current lows?
Source Fool.com